These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 36870561)

  • 1. Effect of adding PCSK9 inhibitors to lipid-lowering interventions on arterial stiffness: A systematic review and meta-analysis.
    Cavero-Redondo I; Moreno-Herraiz N; Del Saz-Lara A; Otero-Luis I; Recio-Rodriguez JI; Saz-Lara A
    Eur J Clin Invest; 2024 Jun; ():e14269. PubMed ID: 39031778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 inhibitors ameliorate arterial stiffness in ACS patients: evidences from Mendelian randomization, a retrospective study and basic experiments.
    Xu L; Wang L; Wang Y; Wang Y; Jiang Y; Du P; Cheng J; Zhang C; Wang R; Jiao T; Xing L; Ma J; Li J
    Front Med (Lausanne); 2024; 11():1408760. PubMed ID: 38860206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
    Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
    Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors.
    Likozar AR; Šebeštjen M
    Cardiovasc Ultrasound; 2023 Aug; 21(1):15. PubMed ID: 37580777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of PCSK9 inhibition on plasma levels of small dense low density lipoprotein-cholesterol and 7-ketocholesterol.
    Mahmood T; Miles JR; Minnier J; Tavori H; DeBarber AE; Fazio S; Shapiro MD
    J Clin Lipidol; 2024; 18(1):e50-e58. PubMed ID: 37923663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early use of PCSK9 inhibitors in the prognosis of patients with acute coronary syndrome by protecting vascular endothelial function.
    Xu L; Wang Y; Wang Y; Wang L; Du P; Cheng J; Zhang C; Jiao T; Xing L; Tapu MSR; Jia H; Li J
    Pharmacology; 2024 Jul; ():. PubMed ID: 38964284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex Differences in Cardiovascular Outcomes and Cholesterol-Lowering Efficacy of PCSK9 Inhibitors: Systematic Review and Meta-Analysis.
    Rivera FB; Cha SW; Aparece JP; Rocimo A; Ong BA; Golbin JM; Alfonso PG; Enkhmaa B; Khan SU; Cainzos-Achirica M; Volgman AS; Navar AM; Shah NP
    JACC Adv; 2023 Nov; 2(9):100669. PubMed ID: 38938736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strike early-strike strong lipid-lowering strategy with PCSK9i in ACS patients. Real-world evidence from AT-TARGET-IT registry.
    Gargiulo P; Basile C; Galasso G; Bellino M; D'Elia D; Patti G; Bosco M; Prinetti M; Andò G; Campanella F; Taverna G; Calabrò P; Cesaro A; Fimiani F; Catalano A; Varbella F; Corleto A; Barillà F; Muscoli S; Musumeci G; Delnevo F; Giallauria F; Napoli R; Porto I; Polimeni A; Quarta R; Maloberti A; Merlini PA; De Luca L; Casu G; Brunetti ND; Crisci M; Paloscia L; Bilato C; Indolfi C; Marzano F; Fontanarosa S; Buonocore D; Parlati ALM; Nardi E; Prastaro M; Soricelli A; Salvatore M; Paolillo S; Perrone-Filardi P;
    Eur J Prev Cardiol; 2024 May; ():. PubMed ID: 38788773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Improves the Vascular Function of Arteriovenous Fistula in Rats with Hyperglycemia.
    Wang YC; Ho HY; Kuo LP; Fang SY; Chiu MH; Liu ZY; Lam CF; Huang YC; Roan JN
    Acta Cardiol Sin; 2024 Jul; 40(4):421-436. PubMed ID: 39045368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex X Time Interactions in Lp(a) and LDL-C Response to Evolocumab.
    Fogacci F; Yerlitaş Sİ; Giovannini M; Zararsız G; Lido P; Borghi C; Cicero AFG
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Xanthine Oxidase Inhibition on Arterial Stiffness in Patients With Chronic Heart Failure.
    Alem MM; Alshehri AM; Cahusac PM; Walters MR
    Clin Med Insights Cardiol; 2018; 12():1179546818779584. PubMed ID: 29899669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies.
    Qureshi Z; Khanzada M; Safi A; Fatima E; Altaf F; Vittorio TJ
    Ann Med Surg (Lond); 2024 May; 86(5):2818-2827. PubMed ID: 38694324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chinese expert consensus on the diagnosis and treatment of coronary microvascular diseases (2023 Edition).
    Chen W; Ni M; Huang H; Cong H; Fu X; Gao W; Yang Y; Yu M; Song X; Liu M; Yuan Z; Zhang B; Wang Z; Wang Y; Chen Y; Zhang C; Zhang Y
    MedComm (2020); 2023 Dec; 4(6):e438. PubMed ID: 38116064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aging of the Arterial System.
    Castelli R; Gidaro A; Casu G; Merella P; Profili NI; Donadoni M; Maioli M; Delitala AP
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic PCSK9 inhibitor therapy leads to sustained improvements in endothelial function, arterial stiffness, and microvascular function.
    Schremmer J; Busch L; Baasen S; Heinen Y; Sansone R; Heiss C; Kelm M; Stern M
    Microvasc Res; 2023 Jul; 148():104513. PubMed ID: 36870561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
    Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
    J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
    Edmiston JB; Brooks N; Tavori H; Minnier J; Duell B; Purnell JQ; Kaufman T; Wojcik C; Voros S; Fazio S; Shapiro MD
    J Clin Lipidol; 2017; 11(3):667-673. PubMed ID: 28506388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.